Track market-moving stories before they get noisy

Louisbourg Investments Inc. lowered its position in shares of CenterPoint Energy, Inc. (NYSE:CNP – Free Report) by 45.1% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 17,760 shares of the utilities provider’s stock after selling 14,574 shares during the quarter. Louisbourg Investments Inc.’s holdings in CenterPoint Energy were worth $654,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Deutsche Bank AG purchased a new position in CenterPoint Energy in the second quarter valued at approximately $770,871,000. Bank of America Corp DE acquired a new position in CenterPoint Energy during the second quarter valued at approximately $332,753,000. Legal & General Group Plc acquired a new position in CenterPoint Energy during the second quarter valued at approximately $250,273,000. GQG Partners LLC acquired a new position in CenterPoint Energy during the second quarter valued at approximately $176,574,000. Finally, Bank of New York Mellon Corp purchased a new stake in CenterPoint Energy during the second quarter worth approximately $163,893,000. Hedge funds and other institutional investors own 91.77% of the company’s stock.

Wall Street Analyst Weigh In Several equities research analysts have recently issued reports on CNP shares. JPMorgan Chase & Co. dropped their price objective on shares of CenterPoint Energy from $46.00 to $44.00 and set a “neutral” rating for the company in a research report on Tuesday, October 13th. Citigroup cut their target price on shares of CenterPoint Energy from $47.00 to $43.00 and set a “neutral” rating on the stock in a research note on Thursday, October 8th. Royal Bank Of Canada began coverage on shares of CenterPoint Energy in a research note on Tuesday, September 15th. They issued a “sector perform” rating and a $40.00 target price on the stock. BTIG Research initiated coverage on shares of CenterPoint Energy in a report on Tuesday, June 30th. They set a “neutral” rating on the stock. Finally, Truist Financial decreased their price target on shares of CenterPoint Energy from $46.00 to $44.00 and set a “buy” rating for the company in a research report on Monday, October 12th. Nine analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $44.06.

Get Our Latest Stock Report on CNP CenterPoint Energy Trading Up 1.7% NYSE CNP opened at $40.24 on Wednesday. The company’s fifty day simple moving average is $38.97 and its 200-day simple moving average is $41.50. CenterPoint Energy, Inc. has a 52 week low of $36.37 and a 52 week high of $45.26. The company has a current ratio of 1.12, a quick ratio of 0.97 and a debt-to-equity ratio of 1.95. The stock has a market cap of $26.51 billion, a P/E ratio of 23.67, a PEG ratio of 2.61 and a beta of 0.47.

CenterPoint Energy (NYSE:CNP – Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The utilities provider reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.03. CenterPoint Energy had a net margin of 11.61% and a return on equity of 11.10%. The business had revenue of $2.15 billion during the quarter, compared to analyst estimates of $2.12 billion. During the same period last year, the business earned $0.29 EPS. CenterPoint Energy has set its FY 2026 guidance at 1.890-1.910 EPS. Equities research analysts predict that CenterPoint Energy, Inc. will post 1.91 EPS for the current fiscal year.

CenterPoint Energy Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Thursday, November 19th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, November 19th. CenterPoint Energy’s dividend payout ratio is presently 56.47%.

(Free Report)

CenterPoint Energy, Inc is a public utility holding company that provides electric and natural gas energy services in the United States. Its operations include electric transmission and distribution, natural gas distribution, and related infrastructure services for residential, commercial, and industrial customers.

The company is the primary electric delivery utility for the Houston, Texas, area and operates electric and natural gas businesses in several states, including Texas, Indiana, Ohio, Louisiana, and Mississippi.

Recommended Stories Five stocks we like better than CenterPoint Energy Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling? Halliburton Gains Traction: Multiyear Upcycle Ahead Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge

Receive News & Ratings for CenterPoint Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CenterPoint Energy and related companies with MarketBeat.com's FREE daily email newsletter.

Final European Commission decision expected during Q4 2026  | Source: Ascendis Pharma

COPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for once-weekly TransCon CNP (navepegritide) in the European Union for the treatment of achondroplasia in children two years of age and older whose epiphyses are not closed. The final European Commission (EC) decision on Ascendis Pharma’s Marketing Authorisation Application (MAA) is expected during Q4 2026.

“We are pleased to receive this positive opinion reflecting the unique profile of TransCon CNP,” said Jan Mikkelsen, President and Chief Executive Officer at Ascendis Pharma. “With a highly favorable response from the achondroplasia community to its differentiated profile, TransCon CNP remains a foundational product in our growth disorder portfolio, positioned to support our Vision 2030 objectives.”

CHMP adopted its positive opinion following its review of the MAA for TransCon CNP, which included clinical data from three randomized, double-blind, placebo-controlled clinical trials and up to three years of open-label extension data. The pivotal ApproaCH Trial data is available in JAMA Pediatrics.i

TransCon CNP was designated as an orphan medicine during its development. EMA will now review the information available to date to determine if the orphan designation can be maintained.

If authorized by the EC, Ascendis expects its first EU launch of TransCon CNP under the brand name YUVIWEL® to be in Germany during Q1 2027.

About TransCon CNP
TransCon CNP is a prodrug of C-type natriuretic peptide (CNP) administered once weekly, designed to provide continuous exposure of active CNP to receptors on tissues throughout the body to counteract the overactive FGFR3 signaling in achondroplasia. It is the only approved therapy to provide continuous systemic exposure to active CNP over the weekly dosing interval. In February 2026, TransCon CNP was approved by the U.S. Food & Drug Administration (FDA) under the trade name YUVIWEL® to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. A final decision by the European Commission is anticipated in the fourth quarter of 2026.

About Achondroplasia
Achondroplasia is a rare genetic condition arising from a systemic fibroblast growth factor receptor 3 (FGFR3) variant that leads to an imbalance in the effects of the FGFR3 and CNP signaling pathways, estimated to affect more than 250,000 people worldwide. While historically considered a bone growth disorder, the FGFR3 variant seen in achondroplasia is expressed in tissues throughout the body, causing serious muscular, neurological, and cardiorespiratory complications in addition to skeletal dysplasia. Medical complications of achondroplasia vary across different stages of life. Throughout infancy and childhood, observed complications include spinal abnormalities, enlarged brain ventricles, impaired muscle strength and stamina, hearing deficits and chronic ear infections, upper airway obstructions, sleep-disordered breathing, hip problems, leg bowing, and chronic pain; many of these persist or worsen in adulthood. These medical complications can affect physical well-being and quality of life, and may be impacted by a range of individual, clinical, and social factors. Some individuals with achondroplasia require multiple procedures and surgeries to address specific functional or anatomical concerns.

About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to (i) the anticipated timing of the European Commission’s final decision on Ascendis’ Marketing Authorisation Application for TransCon CNP (navepegritide), expected during the fourth quarter of 2026, (ii) the potential for the European Commission to grant marketing authorization for TransCon CNP, (iii) Ascendis’ expectation and anticipated timing for its first European Union launch of TransCon CNP under the brand name YUVIWEL in Germany in the first quarter of 2027, (iv) the potential for TransCon CNP to contribute to patient care and to serve as a foundational product in Ascendis’ growth disorder portfolio in support of its Vision 2030 objectives, (v) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients, and (vi) Ascendis’ use of TransCon to develop new and potentially best-in-class therapies to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third-party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on-market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom-to-operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 11, 2026, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and YUVIWEL® are trademarks owned by the Ascendis Pharma group. © October 2026 Ascendis Pharma A/S. 

Investor Contacts:Media Contact:Chad FugereMelinda BakerAscendis PharmaAscendis Pharma+1 (650) 519-7494+1 (650) 709-8875   ________________________________
i Savarirayan R, McDonnell C, Bacino CA, et al. JAMA Pediatr 2026;180(1):18–25. Published online November 17, 2025. doi:10.1001/jamapediatrics.2025.4771

CenterPoint Energy Sending 355 Mutual Aid Workers to Help Restore Power in Areas Impacted by Hurricane IsaiasPR Newswire

HOUSTON, Oct. 10, 2026

Frontline personnel and contractors deploying to help support Florida Power & Light with
expected outages along the Florida Gulf Coast

, /PRNewswire/ -- To help support customers and communities impacted by Hurricane Isaias along the Northwest Florida Coast, CenterPoint Energy crews are heading out to play an important role in helping neighboring communities recover by restoring Hurricane Isaias-related outages. Through a mutual assistance effort supporting Florida Power & Light, CenterPoint has deployed 105 line workers and released approximately 150 contractor line workers and 100 vegetation management personnel to assist with restoration efforts in Pensacola. The combined workforce is expected to support restoration efforts over the coming days.

"Since we first began monitoring what would become Hurricane Isaias late last week, our team has been preparing diligently, tracking the system and taking proactive steps to support the customers and communities we serve across Greater Houston," said Jason Fabre, Vice President of Distribution and Special Response. "Today, we are proud to answer the call for mutual assistance and support our neighboring communities in other states during their time of need. Our team of 355 CenterPoint employees and contractors will bring the same commitment, focus and dedication to restoring service for customers across the Florida coast as we do here at home."

Supporting Our Neighbors in Florida
Mutual assistance is a hallmark of the utility industry. Utility companies regularly help one another following major storms and other emergency events. When another utility needs support, crews may be requested and deployed to assist with damage assessment, repairs and power restoration. Likewise, when our customers are impacted by outage events, utilities from across the country may answer the call to support restoration efforts. These partnerships help utilities restore service safely and more quickly, strengthen emergency preparedness and response capabilities, and support a coordinated approach to restoring power for customers and communities.

About CenterPoint Energy, Inc.
As the only investor owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and distribution, power generation and natural gas distribution operations that serve more than 7 million metered customers in Indiana, Minnesota and Texas. As of June 30, 2026, the company owned approximately $48.3 billion in assets. With approximately 8,800 employees, CenterPoint Energy and its predecessor companies have been in business for more than 150 years. For more information, visit CenterPointEnergy.com.

For more information, contact:
Communications
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/centerpoint-energy-sending-355-mutual-aid-workers-to-help-restore-power-in-areas-impacted-by-hurricane-isaias-302905021.html

SOURCE CenterPoint Energy

Ausbil Investment Management Ltd bought a new stake in shares of CenterPoint Energy, Inc. (NYSE:CNP – Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The firm bought 58,066 shares of the utilities provider’s stock, valued at approximately $2,137,000. CenterPoint Energy accounts for 1.1% of Ausbil Investment Management Ltd’s holdings, making the stock its 28th biggest position.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd grew its position in CenterPoint Energy by 49.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 709 shares of the utilities provider’s stock valued at $27,000 after acquiring an additional 235 shares in the last quarter. Keating Financial Advisory Services Inc. purchased a new stake in shares of CenterPoint Energy during the second quarter valued at approximately $27,000. MidFirst Bank acquired a new position in shares of CenterPoint Energy during the second quarter worth $38,000. Rexford Capital Inc. acquired a new position in shares of CenterPoint Energy during the first quarter worth $39,000. Finally, Transamerica Financial Advisors LLC purchased a new position in shares of CenterPoint Energy in the second quarter valued at $40,000. 91.77% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth Several equities research analysts recently issued reports on the stock. Wall Street Zen raised shares of CenterPoint Energy from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. Jefferies Financial Group set a $50.00 price objective on shares of CenterPoint Energy in a research report on Thursday, June 18th. BTIG Research initiated coverage on CenterPoint Energy in a research note on Tuesday, June 30th. They set a “neutral” rating for the company. BMO Capital Markets dropped their target price on CenterPoint Energy from $48.00 to $47.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 22nd. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of CenterPoint Energy in a research report on Friday, September 11th. Nine research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.93.

Read Our Latest Research Report on CNP CenterPoint Energy Stock Down 0.1% Shares of NYSE:CNP opened at $38.50 on Thursday. The firm has a market cap of $25.36 billion, a PE ratio of 22.65, a price-to-earnings-growth ratio of 2.55 and a beta of 0.47. The company has a fifty day simple moving average of $39.27 and a 200 day simple moving average of $41.69. The company has a current ratio of 1.12, a quick ratio of 0.97 and a debt-to-equity ratio of 1.95. CenterPoint Energy, Inc. has a 12-month low of $36.37 and a 12-month high of $45.26.

CenterPoint Energy (NYSE:CNP – Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The utilities provider reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.03. The company had revenue of $2.15 billion during the quarter, compared to analyst estimates of $2.12 billion. CenterPoint Energy had a net margin of 11.61% and a return on equity of 11.10%. During the same period last year, the business earned $0.29 EPS. CenterPoint Energy has set its FY 2026 guidance at 1.890-1.910 EPS. On average, equities research analysts anticipate that CenterPoint Energy, Inc. will post 1.91 EPS for the current fiscal year.

CenterPoint Energy Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Thursday, November 19th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Thursday, November 19th. CenterPoint Energy’s payout ratio is currently 56.47%.

CenterPoint Energy Company Profile (Free Report)

CenterPoint Energy, Inc (NYSE:CNP) is an energy delivery company headquartered in Houston, Texas. The company focuses on electric and natural gas utility operations, delivering essential energy to residential, commercial and industrial customers.

CenterPoint operates electric transmission and distribution systems in the Houston metropolitan area and parts of southwestern Indiana. It also provides natural gas distribution and related energy services in several states, including Texas, Indiana, Louisiana, Mississippi and Ohio.

See Also Five stocks we like better than CenterPoint Energy Skydance Just Became a Media Giant—With an $80 Billion Debt Load Could Velo3D Be the Next Defense Buyout Target? Penguin Solutions Is Soaring as AI Memory Demand Explodes Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up Want to see what other hedge funds are holding CNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CenterPoint Energy, Inc. (NYSE:CNP – Free Report).

Receive News & Ratings for CenterPoint Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CenterPoint Energy and related companies with MarketBeat.com's FREE daily email newsletter.

Greater Houston Resiliency Initiative (GHRI) Update: CenterPoint Energy Continues Monumental Efforts to Build the Most Resilient Coastal GridPR NewswireHOUSTON,

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.

Cash flow can come from bond interest, interest from other types of investments, and, of course, dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures a dividend as a percent of the current stock price. Many academic studies show that dividends make up large portions of long-term returns, and in many cases, dividend contributions surpass one-third of total returns.

Headquartered in Houston, CenterPoint Energy (CNP - Free Report) is a Utilities stock that has seen a price change of -4.02% so far this year. Currently paying a dividend of $0.24 per share, the company has a dividend yield of 2.61%. In comparison, the Utility - Electric Power industry's yield is 3.29%, while the S&P 500's yield is 1.43%.

Looking at dividend growth, the company's current annualized dividend of $0.96 is up 9.1% from last year. Over the last 5 years, CenterPoint Energy has increased its dividend 5 times on a year-over-year basis for an average annual increase of 8.33%. Looking ahead, future dividend growth will be dependent on earnings growth and payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. CenterPoint's current payout ratio is 48%, meaning it paid out 48% of its trailing 12-month EPS as dividend.

Looking at this fiscal year, CNP expects solid earnings growth. The Zacks Consensus Estimate for 2026 is $1.91 per share, representing a year-over-year earnings growth rate of 8.52%.

From greatly improving stock investing profits and reducing overall portfolio risk to providing tax advantages, investors like dividends for a variety of different reasons. However, not all companies offer a quarterly payout.

Big, established firms that have more secure profits are often seen as the best dividend options, but it's fairly uncommon to see high-growth businesses or tech start-ups offer their stockholders a dividend. Income investors have to be mindful of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. That said, they can take comfort from the fact that CNP is not only an attractive dividend play, but is also a compelling investment opportunity with a Zacks Rank of #2 (Buy).

Houston, TX, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CenterPoint Energy, Inc. (NYSE: CNP) has scheduled a conference call for Tuesday, October 27, 2026, at 7:00 a.m. Central time or 8:00 a.m. Eastern time, to discuss Third Quarter results. Earnings will be released on the same day before the market opens.

CenterPoint Energy will provide a live audio webcast of the conference call, which can be accessed at CenterPointEnergy.com. Click on “Events & Presentations” and the link, “CenterPoint Energy, Inc. Third Quarter 2026 Earnings Conference Call Webcast.” The webcast will be archived on the company’s website for at least one year.

CenterPoint Energy, Inc.

Third Quarter 2026 Earnings Conference Call

Tuesday, October 27, 2026

7:00 a.m. Central / 8:00 a.m. Eastern

About CenterPoint Energy

As the only investor owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and distribution, power generation and natural gas distribution operations that serve more than 7 million metered customers in Indiana, Minnesota, Ohio and Texas. As of June 30, 2026, the company owned approximately $48.3 billion in assets. With approximately 8,800 employees, CenterPoint Energy and its predecessor companies have been in business for more than 150 years. For more information, visit CenterPointEnergy.com.

HOUSTON--(BUSINESS WIRE)--CenterPoint Energy, Inc.'s (NYSE: CNP) Board of Directors today declared a regular quarterly cash dividend of $0.2400 per share on the issued and outstanding shares of Common Stock payable on December 10, 2026, to shareholders of record at the close of business on November 19, 2026.About CenterPoint EnergyAs the only investor-owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and d.

Nykredit A S purchased a new position in shares of CenterPoint Energy, Inc. (NYSE:CNP – Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 20,348 shares of the utilities provider’s stock, valued at approximately $896,000.

Several other large investors also recently added to or reduced their stakes in CNP. Brown Financial Advisors bought a new position in CenterPoint Energy in the 2nd quarter worth approximately $200,000. HB Wealth Management LLC raised its holdings in CenterPoint Energy by 17.7% during the 2nd quarter. HB Wealth Management LLC now owns 34,657 shares of the utilities provider’s stock valued at $1,526,000 after acquiring an additional 5,207 shares during the period. Saudi Central Bank lifted its position in shares of CenterPoint Energy by 89.6% during the second quarter. Saudi Central Bank now owns 45,701 shares of the utilities provider’s stock worth $2,013,000 after acquiring an additional 21,603 shares in the last quarter. AlphaGrep UK Ltd bought a new position in shares of CenterPoint Energy in the second quarter worth $472,000. Finally, Shah Wealth Advisors LLC bought a new position in shares of CenterPoint Energy in the second quarter worth $470,000. Hedge funds and other institutional investors own 91.77% of the company’s stock.

CenterPoint Energy Trading Down 1.9% Shares of CenterPoint Energy stock opened at $37.12 on Thursday. The company has a debt-to-equity ratio of 1.95, a current ratio of 1.12 and a quick ratio of 0.97. CenterPoint Energy, Inc. has a 1 year low of $37.04 and a 1 year high of $45.26. The firm has a market cap of $24.45 billion, a PE ratio of 21.84, a PEG ratio of 2.50 and a beta of 0.46. The company has a 50 day simple moving average of $40.50 and a two-hundred day simple moving average of $42.12.

CenterPoint Energy (NYSE:CNP – Get Free Report) last issued its quarterly earnings results on Tuesday, July 28th. The utilities provider reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.03. CenterPoint Energy had a net margin of 11.61% and a return on equity of 11.10%. The firm had revenue of $2.15 billion for the quarter, compared to analyst estimates of $2.12 billion. During the same quarter in the prior year, the firm earned $0.29 EPS. CenterPoint Energy has set its FY 2026 guidance at 1.890-1.910 EPS. Analysts expect that CenterPoint Energy, Inc. will post 1.91 earnings per share for the current fiscal year. CenterPoint Energy Increases Dividend The company also recently declared a quarterly dividend, which was paid on Thursday, September 10th. Shareholders of record on Thursday, August 20th were given a dividend of $0.24 per share. The ex-dividend date was Thursday, August 20th. This is a positive change from CenterPoint Energy’s previous quarterly dividend of $0.23. This represents a $0.96 dividend on an annualized basis and a yield of 2.6%. CenterPoint Energy’s dividend payout ratio (DPR) is 56.47%.

Analyst Upgrades and Downgrades CNP has been the topic of a number of analyst reports. Royal Bank Of Canada started coverage on CenterPoint Energy in a research note on Tuesday, September 15th. They set a “sector perform” rating and a $40.00 price objective on the stock. Jefferies Financial Group set a $50.00 target price on CenterPoint Energy in a research note on Thursday, June 18th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of CenterPoint Energy in a report on Friday, September 11th. BMO Capital Markets decreased their price target on CenterPoint Energy from $48.00 to $47.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 22nd. Finally, BTIG Research began coverage on shares of CenterPoint Energy in a research note on Tuesday, June 30th. They issued a “neutral” rating on the stock. Nine investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.93.

View Our Latest Stock Analysis on CenterPoint Energy

CenterPoint Energy Profile (Free Report)

CenterPoint Energy, Inc (NYSE:CNP) is an energy delivery company headquartered in Houston, Texas. Its primary businesses include electric transmission and distribution and natural gas distribution, with operations focused on delivering energy to residential, commercial and industrial customers rather than producing most of the energy it supplies.

CenterPoint operates electric utility infrastructure in the Houston metropolitan area and in southwestern Indiana. The company also provides natural gas distribution services in Indiana, Louisiana, Mississippi and Ohio.

Read More Five stocks we like better than CenterPoint Energy Chips to Bots: Qualcomm’s Agentic AI Breakout Ciena Fell 40%—Now One Analyst Sees 50% Upside Energy Transfer Taps the AI Power Boom Viking’s Obesity Edge May Be Staying Power, Not Weight Loss Want to see what other hedge funds are holding CNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CenterPoint Energy, Inc. (NYSE:CNP – Free Report).

Receive News & Ratings for CenterPoint Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CenterPoint Energy and related companies with MarketBeat.com's FREE daily email newsletter.

HOUSTON--(BUSINESS WIRE)--CenterPoint Energy Resources Corp. (“CERC”), an indirect, wholly owned subsidiary of CenterPoint Energy, Inc. (NYSE: CNP), announced today the early results of the previously announced cash tender offers (each, a “Tender Offer” and collectively, the “Tender Offers”) for up to $350,000,000 aggregate purchase price (excluding Accrued Interest) (the “Aggregate Maximum Amount”) of the 4.10% Senior Notes due 2047 (the “2047 Notes”), 4.40% Senior Notes due 2032 (the “2032 No.

CenterPoint (CNP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Investors interested in stocks from the Utility - Electric Power sector have probably already heard of Enel SpA (ENLAY - Free Report) and CenterPoint Energy (CNP - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.

There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.

Both Enel SpA and CenterPoint Energy have a Zacks Rank of #2 (Buy) right now. This means that both companies have witnessed positive earnings estimate revisions, so investors should feel comfortable knowing that both of these stocks have an improving earnings outlook. But this is just one factor that value investors are interested in.

Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.

Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.

ENLAY currently has a forward P/E ratio of 11.67, while CNP has a forward P/E of 19.90. We also note that ENLAY has a PEG ratio of 1.87. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. CNP currently has a PEG ratio of 2.51.

Another notable valuation metric for ENLAY is its P/B ratio of 1.77. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, CNP has a P/B of 2.13.

These metrics, and several others, help ENLAY earn a Value grade of A, while CNP has been given a Value grade of C.

Both ENLAY and CNP are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that ENLAY is the superior value option right now.

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.

Cash flow can come from bond interest, interest from other types of investments, and, of course, dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures a dividend as a percent of the current stock price. Many academic studies show that dividends make up large portions of long-term returns, and in many cases, dividend contributions surpass one-third of total returns.

Headquartered in Houston, CenterPoint Energy (CNP - Free Report) is a Utilities stock that has seen a price change of 2.01% so far this year. The energy delivery company is paying out a dividend of $0.24 per share at the moment, with a dividend yield of 2.45% compared to the Utility - Electric Power industry's yield of 3.2% and the S&P 500's yield of 1.41%.

Looking at dividend growth, the company's current annualized dividend of $0.96 is up 9.1% from last year. Over the last 5 years, CenterPoint Energy has increased its dividend 5 times on a year-over-year basis for an average annual increase of 8.33%. Looking ahead, future dividend growth will be dependent on earnings growth and payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. CenterPoint's current payout ratio is 48%, meaning it paid out 48% of its trailing 12-month EPS as dividend.

Looking at this fiscal year, CNP expects solid earnings growth. The Zacks Consensus Estimate for 2026 is $1.91 per share, with earnings expected to increase 8.52% from the year ago period.

Investors like dividends for many reasons; they greatly improve stock investing profits, decrease overall portfolio risk, and carry tax advantages, among others. But, not every company offers a quarterly payout.

High-growth firms or tech start-ups, for example, rarely provide their shareholders a dividend, while larger, more established companies that have more secure profits are often seen as the best dividend options. During periods of rising interest rates, income investors must be mindful that high-yielding stocks tend to struggle. That said, they can take comfort from the fact that CNP is not only an attractive dividend play, but is also a compelling investment opportunity with a Zacks Rank of #2 (Buy).

 | Source: Ascendis Pharma

– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment 

– Treatment with TransCon CNP increased linear growth in the sentinel cohort, with an improvement in ACH-specific supine length Z-score of +0.42 from baseline through Week 52

– Treatment with TransCon CNP was generally well tolerated, with no reports of injection site reactions over the 52-week treatment period

COPENHAGEN, Denmark, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 52 data from the open-label sentinel cohort portion of the reACHin Trial (which preceded the now fully enrolled double-blinded portion of the trial) showing that treatment with once-weekly TransCon CNP (navepegritide) provided stabilization or improvement in foramen magnum stenosis (a skull bone narrowing that can lead to dangerous brain stem and spinal cord compression), as well as linear growth benefits, in infants with achondroplasia aged 0 to <2 years. The data were presented by Geneviève Baujat, M.D., clinical geneticist at Necker-Enfants Malades Hospital (Paris), during ESPE 2026, the annual meeting of the European Society for Paediatric Endocrinology.

“The impressive safety profile and data from this sentinel group show how early intervention with weekly TransCon CNP treatment could help address medical complications and growth limitations in infants with achondroplasia,” said Dr. Baujat. “Of note, the stabilization or improvement in foramen magnum stenosis observed in this sentinel cohort indicate the potential for TransCon CNP to address a key concern in this vulnerable population.”

ReACHin is a pivotal Phase 2, randomized, placebo-controlled trial to evaluate the safety, tolerability, and efficacy of once-weekly TransCon CNP at the 100 μg/kg/week dose in at least 66 treatment-naïve infants aged 0 to <2 years with genetically confirmed achondroplasia, followed by a 52-week open-label extension. Prior to recruitment for the 52-week double-blind period, seven infants with achondroplasia (mean age 11.7 months) were enrolled in an open-label sentinel cohort to evaluate the safety and pharmacokinetics (PK) of TransCon CNP in this age group. Additional outcome measures at Week 52 included Achondroplasia Foramen Magnum Score (AFMS, a standardized MRI-based grading system used to evaluate and classify the severity of foramen magnum stenosis), change from baseline in ACH-specific supine length Z-score, and annualized growth velocity (AGV).

Highlights from the Week 52 reACHin Trial Sentinel Cohort Data

Treatment with TransCon CNP led to stable or improved cranio-cervical junction health at Week 52, as measured by: AFMS was stable or improved between baseline and Week 52 in all childrenMean change from baseline in sagittal diameter of foramen magnum was +3.15 mmThere were no decompression surgeries during the 52-week period Treatment with TransCon CNP increased linear growth at Week 52: Mean change from baseline in ACH-specific supine length Z-score was +0.42Mean AGV was 9.9 cm/year PK was comparable to that observed in older children, supporting the 100 μg/kg/week doseTransCon CNP was generally well tolerated and the safety data were consistent with those previously reported in other trials: No reports of injection site reactions over the 52-week treatment periodNo deaths, fractures, bone-related safety events, or symptomatic hypotensionNo AEs were assessed by investigators as related to treatment and no AEs led to treatment disruption or discontinuation or to trial withdrawal “Achondroplasia can affect many aspects of a child’s health and quality of life. For this reason, and not for height alone, we believe families should have broad access to as many treatment options as possible for their child,” said Susana Noval, Director of Fundación ALPE Acondroplasia, an advocacy organization in Spain. “This initial infant data for TransCon CNP demonstrates a very encouraging safety and tolerability profile, and we look forward to following the study as more data emerge.”

About TransCon CNP
TransCon CNP is a prodrug of C-type natriuretic peptide (CNP) administered once weekly, designed to provide continuous exposure of active CNP to receptors on tissues throughout the body to counteract the overactive FGFR3 signaling in achondroplasia. In February 2026, TransCon CNP was approved by the U.S. Food & Drug Administration (FDA) under the trade name YUVIWEL® to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. Ascendis Pharma’s Marketing Authorisation Application for YUVIWEL is under review by the European Medicines Agency, with a regulatory decision anticipated in the fourth quarter of 2026.

About Achondroplasia
Achondroplasia is a rare genetic condition arising from a systemic fibroblast growth factor receptor 3 (FGFR3) variant that leads to an imbalance in the effects of the FGFR3 and CNP signaling pathways, estimated to affect more than 250,000 people worldwide. While historically considered a bone growth disorder, the FGFR3 variant seen in achondroplasia is expressed in tissues throughout the body, causing serious muscular, neurological, and cardiorespiratory complications in addition to skeletal dysplasia. Medical complications of achondroplasia vary across different stages of life. Throughout infancy and childhood, observed complications include spinal abnormalities, enlarged brain ventricles, impaired muscle strength and stamina, hearing deficits and chronic ear infections, upper airway obstructions, sleep-disordered breathing, hip problems, leg bowing, and chronic pain; many of these persist or worsen in adulthood. These medical complications can affect physical well-being and quality of life, and may be impacted by a range of individual, clinical, and social factors. Some individuals with achondroplasia require multiple procedures and surgeries to address specific functional or anatomical concerns.

About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to (i) the potential for TransCon CNP (navepegritide) to address foramen magnum stenosis and support linear growth in infants with achondroplasia, (ii) the potential safety, tolerability, and efficacy benefits of TransCon CNP in infants based on reACHin Trial sentinel cohort data, (iii) the anticipated timing of a regulatory decision from the European Medicines Agency regarding YUVIWEL, (iv) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients, and (v) Ascendis’ use of TransCon to develop new and potentially best-in-class therapies to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third‑party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on‑market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom‑to‑operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 11, 2026, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon®, and YUVIWEL® are trademarks owned by the Ascendis Pharma group. © September 2026 Ascendis Pharma A/S.

Investor Contacts:Media Contact:Chad FugereMelinda BakerAscendis PharmaAscendis Pharma+1 (650) 519-7494+1 (650) 709-8875

Hsbc Holdings PLC grew its holdings in shares of CenterPoint Energy, Inc. (NYSE:CNP – Free Report) by 11.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,116,625 shares of the utilities provider’s stock after buying an additional 113,888 shares during the period. Hsbc Holdings PLC owned 0.17% of CenterPoint Energy worth $49,316,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Beacon Pointe Advisors LLC acquired a new stake in CenterPoint Energy in the 2nd quarter valued at approximately $606,000. Kimelman & Baird LLC acquired a new position in CenterPoint Energy during the 2nd quarter worth $62,000. Pin Oak Investment Advisors Inc. acquired a new position in CenterPoint Energy during the 2nd quarter worth $44,000. Rakuten Investment Management Inc. bought a new position in shares of CenterPoint Energy in the second quarter worth $4,789,000. Finally, Empowered Funds LLC acquired a new position in shares of CenterPoint Energy during the second quarter valued at $1,559,000. 91.77% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets A number of equities research analysts recently weighed in on CNP shares. Wall Street Zen upgraded shares of CenterPoint Energy from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. BTIG Research assumed coverage on shares of CenterPoint Energy in a research report on Tuesday, June 30th. They issued a “neutral” rating for the company. Wolfe Research reissued an “outperform” rating and set a $49.00 target price on shares of CenterPoint Energy in a research note on Wednesday, July 29th. KeyCorp dropped their price target on shares of CenterPoint Energy from $47.00 to $46.00 and set an “overweight” rating on the stock in a research report on Thursday, July 23rd. Finally, JPMorgan Chase & Co. upped their price target on shares of CenterPoint Energy from $45.00 to $47.00 and gave the stock a “neutral” rating in a research note on Thursday, July 16th. Nine equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $45.36.

Get Our Latest Stock Report on CNP CenterPoint Energy Price Performance NYSE CNP opened at $39.63 on Tuesday. The stock has a market capitalization of $26.11 billion, a P/E ratio of 23.31, a P/E/G ratio of 2.62 and a beta of 0.46. CenterPoint Energy, Inc. has a 1 year low of $37.13 and a 1 year high of $45.26. The business’s fifty day moving average is $41.79 and its two-hundred day moving average is $42.50. The company has a debt-to-equity ratio of 1.95, a quick ratio of 0.97 and a current ratio of 1.12.

CenterPoint Energy (NYSE:CNP – Get Free Report) last released its quarterly earnings data on Tuesday, July 28th. The utilities provider reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.03. The business had revenue of $2.15 billion during the quarter, compared to analyst estimates of $2.12 billion. CenterPoint Energy had a return on equity of 11.10% and a net margin of 11.61%.During the same period last year, the company posted $0.29 EPS. CenterPoint Energy has set its FY 2026 guidance at 1.890-1.910 EPS. On average, research analysts forecast that CenterPoint Energy, Inc. will post 1.91 earnings per share for the current fiscal year.

CenterPoint Energy Increases Dividend The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Thursday, August 20th will be issued a dividend of $0.24 per share. This is a positive change from CenterPoint Energy’s previous quarterly dividend of $0.23. This represents a $0.96 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, August 20th. CenterPoint Energy’s dividend payout ratio (DPR) is currently 56.47%.

CenterPoint Energy Company Profile (Free Report)

CenterPoint Energy, Inc (NYSE: CNP) is a Houston-based regulated utility company that provides electric and natural gas delivery services and related infrastructure operations. The company’s principal activities center on the transmission and distribution of electricity in the greater Houston metropolitan area and the distribution of natural gas to customers across several states in the Midwest and South. As a vertically integrated utility, CenterPoint focuses on the reliable delivery of energy through owned and operated networks of lines, pipelines and associated facilities.

CenterPoint’s core businesses include regulated electric transmission and distribution services, regulated natural gas distribution, and the operation and maintenance of energy infrastructure.

Recommended Stories Five stocks we like better than CenterPoint Energy 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane

Receive News & Ratings for CenterPoint Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CenterPoint Energy and related companies with MarketBeat.com's FREE daily email newsletter.

Beacon Pointe Advisors LLC acquired a new position in shares of CenterPoint Energy, Inc. (NYSE:CNP – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 13,763 shares of the utilities provider’s stock, valued at approximately $606,000.

A number of other hedge funds have also modified their holdings of CNP. Kimelman & Baird LLC bought a new stake in CenterPoint Energy in the 2nd quarter valued at approximately $62,000. Pin Oak Investment Advisors Inc. bought a new position in shares of CenterPoint Energy during the 2nd quarter worth approximately $44,000. Rakuten Investment Management Inc. bought a new position in shares of CenterPoint Energy during the 2nd quarter worth approximately $4,789,000. Empowered Funds LLC acquired a new stake in shares of CenterPoint Energy in the second quarter valued at approximately $1,559,000. Finally, United Capital Financial Advisors LLC acquired a new stake in shares of CenterPoint Energy in the second quarter valued at approximately $868,000. 91.77% of the stock is currently owned by institutional investors.

CenterPoint Energy Stock Performance Shares of CNP opened at $39.69 on Tuesday. The firm has a 50-day moving average of $42.25 and a 200-day moving average of $42.59. CenterPoint Energy, Inc. has a one year low of $36.60 and a one year high of $45.26. The company has a market cap of $26.14 billion, a PE ratio of 23.35, a price-to-earnings-growth ratio of 2.32 and a beta of 0.46. The company has a debt-to-equity ratio of 1.95, a current ratio of 1.12 and a quick ratio of 0.97.

CenterPoint Energy (NYSE:CNP – Get Free Report) last released its quarterly earnings data on Tuesday, July 28th. The utilities provider reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.03. CenterPoint Energy had a net margin of 11.61% and a return on equity of 11.10%. The company had revenue of $2.15 billion for the quarter, compared to analyst estimates of $2.12 billion. During the same period in the previous year, the business earned $0.29 EPS. CenterPoint Energy has set its FY 2026 guidance at 1.890-1.910 EPS. As a group, equities analysts forecast that CenterPoint Energy, Inc. will post 1.91 earnings per share for the current year. CenterPoint Energy Increases Dividend The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Thursday, August 20th will be paid a dividend of $0.24 per share. The ex-dividend date is Thursday, August 20th. This represents a $0.96 annualized dividend and a dividend yield of 2.4%. This is an increase from CenterPoint Energy’s previous quarterly dividend of $0.23. CenterPoint Energy’s dividend payout ratio is presently 56.47%.

Analyst Ratings Changes CNP has been the subject of several recent research reports. KeyCorp reduced their target price on shares of CenterPoint Energy from $47.00 to $46.00 and set an “overweight” rating for the company in a report on Thursday, July 23rd. Weiss Ratings reissued a “buy (b)” rating on shares of CenterPoint Energy in a research report on Monday, June 15th. Jefferies Financial Group set a $50.00 price objective on shares of CenterPoint Energy in a research note on Thursday, June 18th. Truist Financial decreased their price objective on CenterPoint Energy from $48.00 to $46.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. Finally, BMO Capital Markets lowered their target price on CenterPoint Energy from $48.00 to $47.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 22nd. Nine analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $45.36.

Get Our Latest Research Report on CNP

CenterPoint Energy Profile (Free Report)

CenterPoint Energy, Inc (NYSE: CNP) is a Houston-based regulated utility company that provides electric and natural gas delivery services and related infrastructure operations. The company’s principal activities center on the transmission and distribution of electricity in the greater Houston metropolitan area and the distribution of natural gas to customers across several states in the Midwest and South. As a vertically integrated utility, CenterPoint focuses on the reliable delivery of energy through owned and operated networks of lines, pipelines and associated facilities.

CenterPoint’s core businesses include regulated electric transmission and distribution services, regulated natural gas distribution, and the operation and maintenance of energy infrastructure.

See Also Five stocks we like better than CenterPoint Energy Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season Insiders Are Betting Big on These 3 Healthcare Stocks 3 Stocks for Investors Who Still Believe Cash Is King Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason

Receive News & Ratings for CenterPoint Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CenterPoint Energy and related companies with MarketBeat.com's FREE daily email newsletter.

 | Source: Ascendis Pharma

COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasia Society being held in Toronto, Canada, from August 26-29, 2026, will include an oral presentation of Week 104 data from its pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. The presentation will be given by Carlos Bacino, M.D., FACMG, Professor of Molecular and Human Genetics, Baylor College of Medicine and Texas Children’s Hospital.

“This long-term data reinforces the benefits seen in clinical trials of once-weekly TransCon CNP, which have ranged from durable improvements in height to improvements in lower-extremity alignment, body proportionality, spinal canal dimensions, muscle function, and physical functioning – with a safety and tolerability profile similar to placebo and a low rate of injection site reactions,” said Aimee Shu, Executive Vice President, Chief Medical Officer at Ascendis Pharma. “The results align with improvements in health-related quality of life identified as important to the achondroplasia community and we look forward to sharing them with experts focused on advancing treatment of individuals living with skeletal dysplasia.”

Ascendis presentations at ISDS 2026 include:

ORAL PRESENTATIONFriday
August 28
10:00-10:15am
Session 4Abstract #45
Improved Growth and Physical Functioning in Children with Achondroplasia Treated with Navepegritide in the ApproaCH Trial Open-Label Extension
Presented by Carlos Bacino, M.D.POSTER Wednesday – Saturday
August 26-29
Poster BoardsNumber Needed to Harm Analysis for Injection Site Reactions When Indirect Treatment Comparison (ITC) Is Not Suitable
Authors: Manoj Chevli et al   About TransCon CNP
TransCon CNP is a prodrug of C-type natriuretic peptide (CNP) administered once weekly, designed to provide continuous exposure of active CNP to receptors on tissues throughout the body to counteract the overactive FGFR3 signaling in achondroplasia. In February 2026, TransCon CNP was approved by the U.S. Food & Drug Administration (FDA) under the trade name YUVIWEL® to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. Ascendis Pharma’s Marketing Authorisation Application for YUVIWEL is under review by the European Medicines Agency, with a regulatory decision anticipated in the fourth quarter of 2026.

About Achondroplasia
Achondroplasia is a rare genetic condition arising from a systemic fibroblast growth factor receptor 3 (FGFR3) variant that leads to an imbalance in the effects of the FGFR3 and CNP signaling pathways, estimated to affect more than 250,000 people worldwide. While historically considered a bone growth disorder, the FGFR3 variant seen in achondroplasia is expressed in tissues throughout the body, causing serious muscular, neurological, and cardiorespiratory complications in addition to skeletal dysplasia. Medical complications of achondroplasia vary across different stages of life. Throughout infancy and childhood, observed complications include spinal abnormalities, enlarged brain ventricles, impaired muscle strength and stamina, hearing deficits and chronic ear infections, upper airway obstructions, sleep-disordered breathing, hip problems, leg bowing, and chronic pain; many of these persist or worsen in adulthood. These medical complications can affect physical well-being and quality of life, and may be impacted by a range of individual, clinical, and social factors. Some individuals with achondroplasia require multiple procedures and surgeries to address specific functional or anatomical concerns.

About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ planned oral presentation and poster at ISDS 2026, (ii) the benefits seen in clinical trials of once-weekly TransCon CNP, including durable improvements in height, lower-extremity alignment, body proportionality, spinal canal dimensions, muscle function, and physical functioning, (iii) the safety and tolerability profile of TransCon CNP, including a profile similar to placebo and a low rate of injection site reactions, (iv) the potential for the reported results to align with improvements in health-related quality of life identified as important to the achondroplasia community, (v) Ascendis’ clinical development activities, including the ApproaCH Trial open-label extension, (vi) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients and (vii) Ascendis’ use of TransCon to create new and potentially best-in-class therapies to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third‑party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on‑market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom‑to‑operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 11, 2026, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and YUVIWEL® are trademarks owned by the Ascendis Pharma group. © August 2026 Ascendis Pharma A/S. 

  Investor Contacts:Media Contact:Chad FugereMelinda BakerAscendis PharmaAscendis Pharma+1 (650) 519-7494+1 (650) 709-8875  

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.

While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures a dividend as a percent of the current stock price. Many academic studies show that dividends account for significant portions of long-term returns, with dividend contributions exceeding one-third of total returns in many cases.

Headquartered in Houston, CenterPoint Energy (CNP - Free Report) is a Utilities stock that has seen a price change of 2.48% so far this year. Currently paying a dividend of $0.24 per share, the company has a dividend yield of 2.44%. In comparison, the Utility - Electric Power industry's yield is 3.18%, while the S&P 500's yield is 1.32%.

Looking at dividend growth, the company's current annualized dividend of $0.96 is up 9.1% from last year. Over the last 5 years, CenterPoint Energy has increased its dividend 5 times on a year-over-year basis for an average annual increase of 8.33%. Looking ahead, future dividend growth will be dependent on earnings growth and payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. CenterPoint's current payout ratio is 48%, meaning it paid out 48% of its trailing 12-month EPS as dividend.

Looking at this fiscal year, CNP expects solid earnings growth. The Zacks Consensus Estimate for 2026 is $1.91 per share, representing a year-over-year earnings growth rate of 8.52%.

From greatly improving stock investing profits and reducing overall portfolio risk to providing tax advantages, investors like dividends for a variety of different reasons. But, not every company offers a quarterly payout.

High-growth firms or tech start-ups, for example, rarely provide their shareholders a dividend, while larger, more established companies that have more secure profits are often seen as the best dividend options. During periods of rising interest rates, income investors must be mindful that high-yielding stocks tend to struggle. That said, they can take comfort from the fact that CNP is not only an attractive dividend play, but also represents a compelling investment opportunity with a Zacks Rank of #2 (Buy).

Barrow Hanley Mewhinney & Strauss LLC bought a new position in CenterPoint Energy, Inc. (NYSE:CNP – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,420,488 shares of the utilities provider’s stock, valued at approximately $150,638,000. Barrow Hanley Mewhinney & Strauss LLC owned 0.52% of CenterPoint Energy as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Haverford Trust Co acquired a new position in CenterPoint Energy in the 2nd quarter worth about $393,000. Bank of Nova Scotia acquired a new stake in shares of CenterPoint Energy in the second quarter worth $9,870,000. Elevation Point Wealth Partners LLC bought a new stake in CenterPoint Energy during the second quarter valued at about $1,646,000. Daiichi Life Insurance Co. Ltd. acquired a new stake in CenterPoint Energy in the 2nd quarter valued at approximately $1,276,000. Finally, Commerce Bank bought a new position in CenterPoint Energy during the second quarter worth $3,136,000. 91.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth A number of brokerages recently commented on CNP. Truist Financial cut their target price on CenterPoint Energy from $48.00 to $46.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th. Morgan Stanley dropped their price target on CenterPoint Energy from $40.00 to $39.00 and set an “equal weight” rating for the company in a report on Friday. KeyCorp reduced their target price on shares of CenterPoint Energy from $47.00 to $46.00 and set an “overweight” rating on the stock in a research report on Thursday, July 23rd. JPMorgan Chase & Co. raised their price target on CenterPoint Energy from $45.00 to $47.00 and gave the company a “neutral” rating in a report on Thursday, July 16th. Finally, Wolfe Research reaffirmed an “outperform” rating and set a $49.00 target price on shares of CenterPoint Energy in a report on Wednesday, July 29th. Nine research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $45.36.

Get Our Latest Stock Report on CNP CenterPoint Energy Stock Up 0.1% NYSE:CNP opened at $38.81 on Monday. The firm has a market capitalization of $25.56 billion, a price-to-earnings ratio of 22.83, a price-to-earnings-growth ratio of 2.30 and a beta of 0.46. CenterPoint Energy, Inc. has a twelve month low of $36.60 and a twelve month high of $45.26. The stock’s 50 day moving average price is $42.69 and its two-hundred day moving average price is $42.63. The company has a quick ratio of 0.97, a current ratio of 1.12 and a debt-to-equity ratio of 1.95.

CenterPoint Energy (NYSE:CNP – Get Free Report) last issued its earnings results on Tuesday, July 28th. The utilities provider reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.03. CenterPoint Energy had a net margin of 11.61% and a return on equity of 11.10%. The company had revenue of $2.15 billion for the quarter, compared to analysts’ expectations of $2.12 billion. During the same period in the prior year, the firm earned $0.29 EPS. CenterPoint Energy has set its FY 2026 guidance at 1.890-1.910 EPS. Equities research analysts expect that CenterPoint Energy, Inc. will post 1.91 earnings per share for the current fiscal year.

CenterPoint Energy Increases Dividend The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Thursday, August 20th will be given a dividend of $0.24 per share. This is a positive change from CenterPoint Energy’s previous quarterly dividend of $0.23. This represents a $0.96 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Thursday, August 20th. CenterPoint Energy’s dividend payout ratio (DPR) is currently 56.47%.

CenterPoint Energy Company Profile (Free Report)

CenterPoint Energy, Inc (NYSE: CNP) is a Houston-based regulated utility company that provides electric and natural gas delivery services and related infrastructure operations. The company’s principal activities center on the transmission and distribution of electricity in the greater Houston metropolitan area and the distribution of natural gas to customers across several states in the Midwest and South. As a vertically integrated utility, CenterPoint focuses on the reliable delivery of energy through owned and operated networks of lines, pipelines and associated facilities.

CenterPoint’s core businesses include regulated electric transmission and distribution services, regulated natural gas distribution, and the operation and maintenance of energy infrastructure.

Featured Articles Five stocks we like better than CenterPoint Energy VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

Receive News & Ratings for CenterPoint Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CenterPoint Energy and related companies with MarketBeat.com's FREE daily email newsletter.

21.8.2026 22:09

Zámořské akciové trhy během dnešního obchodování vzrostly a zakončily volatilní týden v kladných číslech. Podporu trhům poskytla příznivá makroekonomická data ukazující nejrychlejší tempo růstu podnikatelské aktivity v USA za poslední čtyři roky. Index Dow Jones si připsal 0,98 % na 53277,01 bodu, širší S&P 500 vzrostl o 0,43 % na 7674,36 bodu a technologický Nasdaq Composite zpevnil o 0,43 % na 26180,46 bodu. Z jednotlivých odvětví indexu S&P 500 dosáhly nejvyšších zisků základní materiály s růstem o 2,2 %, následované zdravotní péčí o 1,3 % a zbytnou spotřebou o 1 %. Naopak nejvýraznější pokles zaznamenaly utility, které ztratily 2,3 %, zatímco energie a reality odepsaly 0,2 % a 0 %. Mezi jednotlivými tituly výrazně posílila společnost Robinhood Markets (HOOD) o 14 %, dále pak Moderna (MRNA) o 8,9 %, Freeport-McMoRan (FCX) o 7,7 %, Coinbase Global (COIN) o 8,2 % a Albemarle Corp (ALB) o 6,8 %. Největší propad naopak postihl společnost Marvell Technology (MRVL), jež oslabila o 5,6 %, a nedařilo se ani firmám Sempra (SRE) se ztrátou 5,1 %, Edison International (EIX) o 4,1 %, American Electric Power (AEP) o 3,8 % a CenterPoint Energy (CNP) s poklesem o 3,6 %. Na komoditních trzích mírně vzrostla cena severoamerické lehké ropy WTI o 0,2 % na 87 dolarů za barel, zatímco spotové zlato posílilo o 2,4 % na 4624,69 dolaru za unci. Americký dolar celkově mírně oslabil. Výnos desetiletých amerických vládních dluhopisů vzrostl o tři bazické body na 4,73 %. Výrazný růst zaznamenal bitcoin, jehož cena stoupla o 6,1 % na 77086,77 dolaru.

Index Dow Jones +0,98 % na 53277,01 b.
S&P 500 +0,43 % na 7674,36 b.
Nasdaq Composite +0,43 % na 26180,46 b.

Index S&P 500 +0,43 % na 7674,36 b. Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Základní materiály +2,2 % Utility -2,3 % Zdravotní péče +1,3 % Energie -0,2 % Finanční sektor +1 % Reality 0 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna Robinhood Markets (HOOD) +14 % Marvell Technology (MRVL) -5,6 % Moderna (MRNA) +8,9 % Sempra (SRE) -5,1 % Coinbase Global (COIN) +8,2 % Edison International (EIX) -4,1 % Freeport-McMoRan (FCX) +7,7 % American Electric Power (AEP) -3,8 % Albemarle Corp (ALB) +6,8 % CenterPoint Energy (CNP) -3,6 %
Daniel Marván
Fio banka, a.s.
Prohlášení

Company outlines opportunity for more than $5 billion in potential savings for Texas electric
customers over the next decade driven by additional large load customers paying for more
infrastructure charges

CenterPoint committed to advancing Governor Abbott's call for greater transparency and clear
standards for new data centers and the requirements established by 2025's Senate Bill 6 to
safeguard Texans

CenterPoint's Greater Houston customers continue to have the lowest infrastructures charges of
any of the investor-owned electric utilities in the state

, /PRNewswire/ -- Today, as part of CenterPoint Energy's ongoing commitment to prioritize customer affordability, the company announced a historic Customer Savings Initiative that offers the opportunity to save Texas electric customers, including CenterPoint's Greater Houston residential, small & medium businesses, and commercial customers, more than $5 billion over the next decade. CenterPoint is committed to advancing Texas Governor Greg Abbott's recent call for greater transparency from developers and the need to set clear standards for the development, construction, and on-going operation of data centers in the state and is already working with customers to meet that call. The company fully supported the customer protections established by Senate Bill 6 in 2025 and has implemented these requirements for these new large load projects included as part of the Customer Savings Initiative.

CenterPoint's newly announced savings initiative, which builds on the company's successful efforts to keep electric rates the lowest of any Texas investor-owned electric transmission and distribution utility, is driven by the planned addition of up to 14 new gigawatts of ERCOT eligible base load and studied load projects. The additional load from these projects would translate into customer savings over the next decade through more and larger customers paying more of the share of fixed grid costs.

"Greater Houston has long been the energy capital of the world, but today it is the home of one of the most diverse economic regions anywhere in the nation. These new projects would help us deliver growth, innovation, and customer savings. We have a once-in-a-generation opportunity to generate historic levels of customer savings of more than $5 billion statewide by leveraging new investment in large projects to build a more affordable, reliable and resilient electric grid for millions of customers. These infrastructure investments and economic development opportunities have the potential to save current customers billions, while also creating jobs and generating millions in local tax revenue to improve our local schools and community public services," said Jason Wells, Chairman & Chief Executive Officer of CenterPoint Energy.

Customer Savings Initiative: An Enduring Commitment to Affordability

The company's Customer Savings Initiative represents CenterPoint's plan to promote greater customer savings and strengthen energy affordability over the coming decade. The pillars of this initiative include the following:

$5 Billion in Statewide Savings: The projected addition of up to 14 gigawatts of eligible base load and studied load projects, along with CenterPoint's continued effort facilitate more growth across the Greater Houston region will help CenterPoint meet future demand from industrial, business and residential growth and will translate into real savings for hard-working Texans. Strengthening the Commitment to Keep Rates Stable: For the past decade, the portion of the customer bill which covers investments in CenterPoint infrastructure has remained stable and increased by just over 1 percent per year (2014-2025), well below the national inflation rate over the same time period. Today, CenterPoint's Greater Houston customers pay the lowest cost per kilowatt hour than any of the other Texas investor-owned electric transmission and distribution utilities. The company achieved this through increasing the customer base, more efficiently financing operations and reducing costs. The addition of new base load will help CenterPoint continue to keep rates stable and affordable over the next decade, providing real energy savings to millions of Texas electric customers.  Committed to National Ratepayer Protection Pledge: CenterPoint signed and supported the recently announced National "Ratepayer Protection Pledge" that would prioritize customer affordability, while enabling private investment responsibly to strengthen the grid and connect more large load customers. Committed to Continuing to Work with Governor Greg Abbott, Legislators, and other state Leaders to Establish Greater Transparency and Clear standards: The framework implemented by the Texas Legislature and the call for greater clarity and clear standards called for by Governor Abbott will help drive continued economic growth, strengthen grid reliability and resiliency, and ensure that new large customers pay the costs associated with connecting and powering their business. CenterPoint stands behind that framework and is partnering with large customers who share that commitment. About CenterPoint Energy, Inc. 

As the only investor owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and distribution, power generation and natural gas distribution operations that serve more than 7 million metered customers in Indiana, Minnesota, Ohio and Texas. As of June 30, 2026, the company owned approximately $48.3 billion in assets. With approximately 8,800 employees, CenterPoint Energy and its predecessor companies have been in business for more than 150 years. For more information, visit CenterPointEnergy.com.

Through expanding customer connections and making critical investments across the service area, the company is delivering on its mission to build an affordable, future-ready energy grid for its nearly 2.9 million Greater Houston customers.

Forward-Looking Statement
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon assumptions of management which are believed to be reasonable at the time made and are subject to significant risks and uncertainties. Actual events and results may differ materially from those expressed or implied by these forward-looking statements. Any statements in this news release regarding future events, such as the potential for large load customer projects and the benefits therefrom (including customer savings, tax revenue and related benefits, and jobs creation), the reliability and resiliency of the electric grid, and any other statements that are not historical facts are forward-looking statements. Each forward-looking statement contained in this news release speaks only as of the date of this release. Important factors that could cause actual results to differ materially from those indicated by the provided forward-looking information include risks and uncertainties relating to: (1) business strategies and strategic initiatives involving CenterPoint Energy or its industry; (2) CenterPoint Energy's ability to fund and invest planned capital, and the timely recovery of its investments; (3) financial market and general economic conditions; (4) the timing and impact of future regulatory, legislative and political actions or developments; and (5) other factors, risks and uncertainties discussed in CenterPoint Energy's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and CenterPoint's Quarterly Report on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026 and other reports CenterPoint Energy or its subsidiaries may file from time to time with the Securities and Exchange Commission.

Media Contact: [email protected]

SOURCE CenterPoint Energy, Inc

Posted by Defense World Staff on Aug 8th, 2026

Empowered Funds LLC grew its holdings in CenterPoint Energy, Inc. (NYSE:CNP – Free Report) by 95.4% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 33,996 shares of the utilities provider’s stock after buying an additional 16,600 shares during the quarter. Empowered Funds LLC’s holdings in CenterPoint Energy were worth $1,467,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Capital Research Global Investors raised its holdings in CenterPoint Energy by 1.1% in the 4th quarter. Capital Research Global Investors now owns 20,941,909 shares of the utilities provider’s stock worth $802,916,000 after acquiring an additional 235,346 shares during the last quarter. Ilmarinen Mutual Pension Insurance Co bought a new position in CenterPoint Energy during the fourth quarter valued at approximately $3,834,000. Principal Financial Group Inc. boosted its holdings in CenterPoint Energy by 6.9% in the fourth quarter. Principal Financial Group Inc. now owns 962,624 shares of the utilities provider’s stock worth $36,907,000 after purchasing an additional 61,740 shares during the last quarter. Artemis Investment Management LLP boosted its holdings in CenterPoint Energy by 96.0% in the fourth quarter. Artemis Investment Management LLP now owns 1,595,867 shares of the utilities provider’s stock worth $61,186,000 after purchasing an additional 781,849 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of CenterPoint Energy by 5.2% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,367,838 shares of the utilities provider’s stock valued at $52,976,000 after purchasing an additional 67,037 shares during the period. 91.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In Several research firms have recently commented on CNP. Morgan Stanley set a $40.00 price objective on CenterPoint Energy in a research note on Wednesday, July 22nd. Bank of America lifted their target price on shares of CenterPoint Energy from $42.00 to $44.00 and gave the company a “neutral” rating in a research note on Wednesday, April 15th. BTIG Research started coverage on CenterPoint Energy in a research report on Tuesday, June 30th. They set a “neutral” rating for the company. Jefferies Financial Group set a $50.00 price target on CenterPoint Energy in a research note on Thursday, June 18th. Finally, Truist Financial reduced their price target on shares of CenterPoint Energy from $48.00 to $46.00 and set a “buy” rating on the stock in a report on Tuesday. Nine equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $45.57.

Read Our Latest Research Report on CNP

CenterPoint Energy Stock Performance Shares of CNP opened at $40.67 on Friday. The company has a current ratio of 1.12, a quick ratio of 0.97 and a debt-to-equity ratio of 1.95. The firm has a market cap of $26.79 billion, a PE ratio of 23.92, a P/E/G ratio of 2.41 and a beta of 0.46. CenterPoint Energy, Inc. has a 12 month low of $36.60 and a 12 month high of $45.26. The stock has a fifty day moving average price of $43.07 and a 200-day moving average price of $42.55.

CenterPoint Energy (NYSE:CNP – Get Free Report) last issued its earnings results on Tuesday, July 28th. The utilities provider reported $0.40 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.03. The firm had revenue of $2.15 billion for the quarter, compared to analyst estimates of $2.12 billion. CenterPoint Energy had a return on equity of 11.10% and a net margin of 11.61%.During the same quarter in the prior year, the firm earned $0.29 earnings per share. CenterPoint Energy has set its FY 2026 guidance at 1.890-1.910 EPS. Equities research analysts predict that CenterPoint Energy, Inc. will post 1.91 earnings per share for the current fiscal year.

CenterPoint Energy Increases Dividend The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Thursday, August 20th will be paid a $0.24 dividend. This is an increase from CenterPoint Energy’s previous quarterly dividend of $0.23. This represents a $0.96 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, August 20th. CenterPoint Energy’s payout ratio is 54.12%.

CenterPoint Energy Profile (Free Report)

CenterPoint Energy, Inc (NYSE: CNP) is a Houston-based regulated utility company that provides electric and natural gas delivery services and related infrastructure operations. The company’s principal activities center on the transmission and distribution of electricity in the greater Houston metropolitan area and the distribution of natural gas to customers across several states in the Midwest and South. As a vertically integrated utility, CenterPoint focuses on the reliable delivery of energy through owned and operated networks of lines, pipelines and associated facilities.

CenterPoint’s core businesses include regulated electric transmission and distribution services, regulated natural gas distribution, and the operation and maintenance of energy infrastructure.

Read More Five stocks we like better than CenterPoint Energy Datadog’s Drop Says More About Expectations Than Earnings D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus Solventum Nears Inflection Point As It Begins to Unlock Value Want to see what other hedge funds are holding CNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CenterPoint Energy, Inc. (NYSE:CNP – Free Report).

Receive News & Ratings for CenterPoint Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CenterPoint Energy and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECetera Investment Advisers Buys 5,788 Shares of Owens Corning Inc $OC

NEXT HEADLINE »Empowered Funds LLC Invests $1.68 Million in PagerDuty $PD

CenterPoint Energy, Inc. (CNP) Q2 2026 Earnings Call July 28, 2026 8:00 AM EDT

Company Participants

Ben Vallejo - Vice President of Investor Relations & Corporate Planning
Jason Wells - President, CEO & Chairman
Christopher Foster - Executive VP & CFO

Conference Call Participants

Shahriar Pourreza - Wells Fargo Securities, LLC, Research Division
Nicholas Campanella - Barclays Bank PLC, Research Division
Julien Dumoulin-Smith - Jefferies LLC, Research Division
Steven Fleishman - Wolfe Research, LLC
Jeremy Tonet - JPMorgan Chase & Co, Research Division
Richard Sunderland - Truist Securities, Inc., Research Division
Sophie Karp - KeyBanc Capital Markets Inc., Research Division
Anthony Crowdell - Mizuho Securities USA LLC, Research Division

Presentation

Operator

Good morning, and welcome to CenterPoint Energy's Second Quarter 2026 Earnings Conference Call with senior management. [Operator Instructions] I will now turn the call over to Ben Vallejo, Vice President of Investor Relations and Corporate Planning. Please go ahead.

Ben Vallejo
Vice President of Investor Relations & Corporate Planning

Good morning, and welcome to CenterPoint's Q2 2026 Earnings Conference Call. Jason Wells, our Chair and CEO; and Chris Foster, our CFO, will discuss the company's second quarter 2026 results. Management will discuss certain topics that will contain projections and other forward-looking information and statements that are based on management's beliefs, assumptions and information currently available to management. These forward-looking statements are subject to risks and uncertainties. Actual results could differ materially based on various factors as noted in our Form 10-Q, other SEC filings and our earnings materials.

We undertake no obligation to revise or update publicly any forward-looking statement other than as required under applicable securities laws. We reported $0.37 per diluted share for the second quarter of 2026 on a GAAP basis. Management will be discussing certain non-GAAP measures on today's call. When providing guidance, we use the non-GAAP EPS measure of diluted adjusted earnings per share on a

3 Data Center Beneficiaries Raising Dividends Up to 60%CenterPoint Energy NYSE: CNP reported second-quarter 2026 GAAP earnings of $0.37 per diluted share and non-GAAP earnings of $0.40 per share, while reaffirming its full-year non-GAAP earnings guidance of $1.89 to $1.91 per share.

Chair and CEO Jason Wells said the midpoint of the guidance range would represent 8% growth from the company’s 2025 delivered results. CenterPoint also reiterated its expectation for non-GAAP earnings-per-share growth at the mid-to-high end of its 7% to 9% annual target range through 2028, followed by 7% to 9% annual growth through 2035.

Get CenterPoint Energy alerts:

The Top 4 Utilities for Value, Yield, and Upside PotentialChief Financial Officer Chris Foster said higher rate recovery added $0.10 per share year over year during the quarter, reflecting updated rates and interim filing mechanisms. Operating and maintenance expense was $0.02 favorable, which Foster attributed to efficiencies in the company’s vegetation-management program. Milder weather in Texas and Indiana reduced results by $0.01 per share, while higher interest expense was also a $0.01 unfavorable factor.

Texas large-load projects advance through ERCOT process CenterPoint said it submitted more than 17 gigawatts of prospective large-load projects through ERCOT’s Batch Zero process. Of those submissions, 14 GW remain eligible for the process, representing more than 65% of Houston Electric’s current 21-GW system peak.

Approximately 10 GW of the eligible projects have both required studies approved and qualify for base-load designation, Wells said. Another 4 GW has one required study approved and may qualify as studied load, subject to ERCOT’s allocation process, which is expected to conclude in April 2027.

The company expects nearly all of the 14 GW of eligible base-load and studied-load projects to be energized by the end of 2030, based on customers’ projected load ramps. Wells said the projects are backed by signed Facilities Extension Agreements, long-term end-user commitments and approximately $900 million of customer cash commitments and security already received.

CenterPoint has begun targeted system-upgrade work for the base-load-eligible projects and expects that work to continue over the next four years. The company said it expects to connect 3 GW in 2027. For later projects, it has begun engineering work and secured long-lead materials, according to Wells.

In addition to transmission-level demand, Wells said Houston Electric is seeing growing distribution-level demand. The company anticipates an additional 2 GW of distribution-level demand over the coming years, driven by advanced manufacturing, population growth and other development in the greater Houston area. During the question-and-answer session, Wells said the 65% growth figure tied to Batch Zero does not include distribution-level customer growth.

Capital plan rises by $1.2 billion CenterPoint increased its 10-year capital investment plan to $66.7 billion from $65.5 billion. The $1.2 billion increase includes $800 million for targeted system upgrades associated with the 14 GW of Batch Zero-eligible projects and $400 million for the Downtown Houston Revitalization Project.

Wells said Houston Electric’s roughly 10 GW of existing hosting capacity allows the company to connect large-load projects with relatively modest incremental investment. CenterPoint estimates the system upgrades can be completed at less than $60 million per gigawatt.

The company also identified approximately $700 million of potential investment opportunities to serve about 3 GW of additional demand that is not currently eligible as base load or studied load in the Batch Zero process. Those investments are not included in the updated capital plan because they remain subject to future batch processes.

Following final site selections for two substation relocations tied to the Downtown Houston project, CenterPoint refined its investment estimate and added $400 million to the plan. The company now expects Houston Electric’s rate base to grow at a compound annual rate of more than 18% over the next three years.

Foster said the revised plan does not require additional equity financing. He cited existing funding capacity following clarification of Corporate Alternative Minimum Tax rules, as well as the expected October 1 closing of the sale of the Ohio Gas local distribution company after regulatory approval. CenterPoint’s planned equity issuance remains unchanged.

The company said potential future financing tailwinds include cash flow from demand charges, potential proceeds or flexibility from marketing temporary generation units, and anticipated tax refunds. CenterPoint expects about $6 million per GW per month in demand-charge cash flow as the expected 14 GW of new load is energized over the next five years. Foster said those cash-flow benefits have not yet been incorporated into the company’s plan.

Customer affordability and Indiana opportunities CenterPoint estimates that the addition of 14 GW of eligible large-load projects in Texas could save residential and commercial electric customers more than $5 billion over the next decade. Foster said the estimate reflects large-load customers absorbing system costs that otherwise would be borne by smaller customers. He described the result as roughly $500 million in annual savings over 10 years.

In Indiana, CenterPoint said it continues to advance a large-load opportunity that could be the single largest load served in its Indiana Electric territory. The company has begun engineering work, ordered long-lead materials and secured a place in the MISO interconnection queue for the project, Wells said.

Wells added that system analysis has identified incremental short- and medium-term capacity that can support discussions with multiple potential customers. CenterPoint has previously estimated that the initial Indiana demand could provide about $250 million in residential customer savings over 15 years.

If Indiana demand exceeds approximately 1.5 GW, Wells said the company could consider pursuing a generation-company structure to support additional generation needs. Investments related to Indiana large-load opportunities would be incremental to CenterPoint’s current base capital plan.

Regulatory and balance-sheet update Foster said CenterPoint recovers approximately 85% of its investments through capital trackers. In Houston Electric, the company filed a distribution capital tracker seeking a $73 million revenue requirement increase, with customer delivery charges expected to be updated in November. It also expects to file a transmission capital tracker next month.

CenterPoint received approval for a Texas Gas capital investment recovery filing seeking approximately $62 million in additional revenue requirement, with rates taking effect in June. The company also plans to file forward-looking rate cases for Minnesota Gas and its North and South Indiana Gas operations by year-end.

CenterPoint invested $1.5 billion during the second quarter and said it had completed about 40% of its planned 2026 capital spending through the first half. The company remains on track to invest $6.8 billion this year.

Its adjusted funds-from-operations-to-debt ratio under Moody’s methodology was 13.4% at the end of the second quarter, nearly 100 basis points higher than in the first quarter. Foster said a portion of an expected Corporate Alternative Minimum Tax refund could add roughly 30 basis points to the metric in the third quarter.

About CenterPoint Energy (NYSE:CNP)CenterPoint Energy, Inc NYSE: CNP is a Houston-based regulated utility company that provides electric and natural gas delivery services and related infrastructure operations. The company's principal activities center on the transmission and distribution of electricity in the greater Houston metropolitan area and the distribution of natural gas to customers across several states in the Midwest and South. As a vertically integrated utility, CenterPoint focuses on the reliable delivery of energy through owned and operated networks of lines, pipelines and associated facilities.

CenterPoint's core businesses include regulated electric transmission and distribution services, regulated natural gas distribution, and the operation and maintenance of energy infrastructure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in CenterPoint Energy Right Now?Before you consider CenterPoint Energy, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CenterPoint Energy wasn't on the list.

While CenterPoint Energy currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

On July 28, 2026, CenterPoint Energy Inc (CNP) released its 8-K filing, detailing its financial performance for the second quarter of 2026. The company reported